1. Rivastigmine is available in both oral capsule and transdermal patch formulations for the treatment of Parkinson's disease dementia. The transdermal patch formulation is generally preferred over oral capsules in clinical practice. Which of the following most accurately explains the pharmacological basis for this preference?
A) The transdermal patch achieves higher peak plasma concentrations than the oral capsule, producing greater cholinesterase inhibition in the cortex and basal forebrain
B) The transdermal patch bypasses first-pass hepatic metabolism entirely, increasing oral bioavailability from approximately 20% to nearly 100% and allowing lower total doses
C) The transdermal patch produces more stable plasma concentrations by avoiding the peak-and-trough profile of oral dosing, resulting in substantially fewer gastrointestinal adverse effects
D) The transdermal patch selectively inhibits butyrylcholinesterase over acetylcholinesterase, providing a mechanistic advantage in Parkinson's disease dementia where butyrylcholinesterase activity is disproportionately elevated
E) The transdermal patch is preferred because it avoids CYP2D6-mediated metabolism, eliminating the clinically significant drug interactions that affect the oral capsule formulation
ANSWER: C
Rationale:
The transdermal patch formulation of rivastigmine delivers drug continuously through the skin, producing sustained and relatively stable plasma concentrations without the sharp peaks that follow oral capsule dosing. The peak plasma concentrations achieved after oral dosing are the primary driver of the cholinergic adverse effects — nausea, vomiting, and diarrhea — that are the main dose-limiting toxicities of rivastigmine. By flattening the concentration-time profile, the patch produces equivalent or superior cholinesterase inhibition with substantially fewer gastrointestinal adverse effects, which is the primary clinical rationale for its preference.
Option A: Option A is incorrect because the patch does not achieve higher peak plasma concentrations than the capsule — the pharmacokinetic advantage is precisely the opposite: lower, more stable peaks rather than higher ones.
Option B: Option B is incorrect because transdermal delivery does bypass first-pass hepatic metabolism, which is pharmacokinetically accurate, but this is not the primary clinical rationale for preferring the patch; the key benefit is GI tolerability through reduced peak concentrations, not a bioavailability calculation.
Option D: Option D is incorrect because both the oral and transdermal formulations of rivastigmine inhibit both acetylcholinesterase and butyrylcholinesterase — the dual inhibition profile is a property of the drug itself, not the delivery route, and there is no selective butyrylcholinesterase advantage conferred by the patch.
Option E: Option E is incorrect because rivastigmine is not significantly metabolized by CYP2D6; it undergoes primarily non-hepatic cholinesterase-mediated hydrolysis at the site of action, so CYP2D6 interactions are not a clinically relevant concern for either formulation.
2. A neurologist explains to residents that the cholinergic deficit in Parkinson's disease dementia (PDD) has a specific pathological basis that distinguishes it from the cholinergic deficit in Alzheimer's disease, with direct implications for pharmacological treatment. Which of the following correctly describes this distinction?
A) The cholinergic deficit in PDD is confined to the hippocampus and spares the basal forebrain nucleus basalis of Meynert, whereas Alzheimer's disease affects both structures equally, making cholinesterase inhibitors more effective in Alzheimer's than in PDD
B) PDD involves loss of nicotinic acetylcholine receptors in the cortex only, while Alzheimer's disease involves loss of both nicotinic and muscarinic receptors; rivastigmine is preferred in PDD because it selectively targets nicotinic receptor-associated cholinesterase
C) The cholinergic deficit in PDD and Alzheimer's disease are pathologically identical, arising from the same pattern of nucleus basalis degeneration; the distinction is purely temporal — Alzheimer's disease progresses faster
D) PDD is characterized by excessive cholinergic activity in the striatum rather than a deficit, which is why anticholinergic agents were historically used for PD motor symptoms; the cortical cholinergic deficit develops only in the final stages of disease
E) The cholinergic deficit in PDD is more severe than in Alzheimer's disease, reflecting cortical Lewy body deposition combined with cholinergic nucleus basalis degeneration that exceeds the cholinergic loss seen in Alzheimer's disease at comparable disease stages
ANSWER: E
Rationale:
The cholinergic deficit in Parkinson's disease dementia arises from a combination of cortical Lewy body deposition and degeneration of the cholinergic nucleus basalis of Meynert that is quantitatively more severe than the cholinergic deficit observed in Alzheimer's disease at comparable stages of cognitive impairment. This greater severity provides the pathophysiological rationale for cholinesterase inhibitor therapy in PDD and helps explain why the cognitive profile of PDD — characterized by prominent executive dysfunction, attention fluctuations, and visuospatial impairment — differs from Alzheimer's disease, where amnestic features predominate.
Option A: Option A is incorrect because the nucleus basalis of Meynert is a primary site of cholinergic degeneration in PDD — it is not spared; cholinesterase inhibitors are effective in PDD precisely because this structure is affected.
Option B: Option B is incorrect because rivastigmine is not preferred in PDD due to selective nicotinic receptor-associated cholinesterase targeting; rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase, and its preference in PDD is based on clinical trial evidence rather than a receptor-selectivity distinction from Alzheimer's disease.
Option C: Option C is incorrect because the cholinergic pathology in PDD and Alzheimer's disease is not identical — Lewy body deposition in the cortex is an additional and distinct pathological substrate in PDD that is not present in typical Alzheimer's disease, and the rate of progression is not the defining distinction.
Option D: Option D is incorrect because excessive striatal cholinergic activity relative to dopaminergic tone does underlie PD motor symptoms (and explains why anticholinergics were used historically), but this is a different circuit from the cortical cholinergic deficit of PDD; the cortical cholinergic deficit begins well before the final stages of disease and is the pharmacological target of rivastigmine.
3. Before initiating pimavanserin for Parkinson's disease psychosis, a specific cardiac safety assessment is recommended in addition to reviewing the black-box warning for increased mortality in elderly patients with dementia-related psychosis. Which of the following correctly identifies this pre-initiation assessment and the ongoing pharmacological concern it reflects?
A) A baseline electrocardiogram to measure the QTc interval is appropriate before initiating pimavanserin, because the drug prolongs cardiac repolarization and this risk is additive with other QTc-prolonging medications the patient may be taking
B) A baseline echocardiogram is required before initiating pimavanserin because the drug causes valvular heart disease through serotonin 5-HT2B receptor activation on cardiac valve interstitial cells, identical to the mechanism of ergot-derived dopamine agonists
C) Baseline cardiac troponin measurement is recommended before initiating pimavanserin because the drug causes a dose-dependent myocarditis that is detectable as an early subclinical troponin elevation in the first four weeks of therapy
D) A 24-hour Holter monitor is required before initiating pimavanserin to establish a baseline heart rate variability profile, because the drug causes progressive autonomic neuropathy affecting cardiac chronotropic function
E) No cardiac pre-initiation assessment is specifically recommended for pimavanserin because its mechanism of action at serotonin receptors does not affect cardiac electrophysiology or cardiac muscle function
ANSWER: A
Rationale:
Pimavanserin prolongs the QTc interval — the corrected measure of cardiac ventricular repolarization time on the electrocardiogram — and this effect is dose-dependent. A prolonged QTc interval increases the risk of torsades de pointes, a potentially fatal ventricular arrhythmia. A baseline electrocardiogram to measure the QTc interval is therefore appropriate before initiating pimavanserin, and the drug should be used cautiously in patients who are already taking other QTc-prolonging medications (including certain antiarrhythmics, antibiotics such as azithromycin, and antifungals). Pimavanserin is contraindicated in patients with known QT prolongation.
Option B: Option B is incorrect because valvular heart disease through 5-HT2B receptor activation is the mechanism responsible for cardiac toxicity with ergot-derived dopamine agonists such as cabergoline and pergolide; pimavanserin acts at 5-HT2A and 5-HT2C receptors and has not been associated with valvulopathy.
Option C: Option C is incorrect because pimavanserin does not cause myocarditis; troponin monitoring is not part of its established safety protocol, and a dose-dependent myocarditis is not a recognized adverse effect of serotonin 5-HT2A/2C inverse agonism.
Option D: Option D is incorrect because Holter monitoring for autonomic neuropathy is not a pre-initiation requirement for pimavanserin; progressive autonomic neuropathy affecting cardiac chronotropic function is not a recognized adverse effect of the drug.
Option E: Option E is incorrect because pimavanserin does have a defined cardiac electrophysiological effect — QTc prolongation — that warrants pre-initiation assessment; the premise that serotonin receptor activity is cardioelectrophysiologically neutral is incorrect for this drug.
4. Both midodrine and droxidopa are FDA-approved for neurogenic orthostatic hypotension in Parkinson's disease, but they raise standing blood pressure through distinct pharmacological mechanisms. Which of the following correctly describes the mechanism of droxidopa and how it differs from midodrine?
A) Droxidopa is a selective alpha-1 adrenergic agonist that acts directly on peripheral arteriolar smooth muscle to increase vascular resistance, while midodrine is a prodrug converted to norepinephrine that acts indirectly through endogenous adrenergic receptors
B) Droxidopa blocks norepinephrine reuptake at peripheral sympathetic nerve terminals, increasing synaptic norepinephrine concentrations and thereby raising vascular tone, while midodrine directly stimulates alpha-1 receptors without requiring a metabolic conversion step
C) Droxidopa is a mineralocorticoid that expands plasma volume by promoting renal sodium retention, raising blood pressure through increased cardiac preload, while midodrine acts directly on peripheral alpha-1 receptors to increase arteriolar resistance
D) Droxidopa is a synthetic amino acid that is converted to norepinephrine by aromatic L-amino acid decarboxylase, raising blood pressure through norepinephrine-mediated adrenergic vasoconstriction, while midodrine is a prodrug converted to desglymidodrine, a direct peripheral alpha-1 agonist
E) Droxidopa and midodrine share the same mechanism — both are prodrugs that are converted to direct alpha-1 adrenergic agonists in peripheral tissues — but droxidopa has a longer duration of action because its active metabolite is more slowly cleared by monoamine oxidase
ANSWER: D
Rationale:
Droxidopa is a synthetic amino acid — structurally related to levodopa — that is converted to norepinephrine by aromatic L-amino acid decarboxylase (AADC), the same enzyme responsible for converting levodopa to dopamine. The resulting norepinephrine acts on peripheral alpha-1 and alpha-2 adrenergic receptors on vascular smooth muscle and on beta-1 receptors on the heart, increasing both vascular resistance and cardiac output to raise blood pressure. Midodrine, by contrast, is a prodrug converted to desglymidodrine, which is a direct selective agonist at peripheral alpha-1 adrenergic receptors, causing arteriolar and venous constriction without generating norepinephrine. This mechanistic distinction means that droxidopa restores a physiological neurotransmitter (norepinephrine) through a biosynthetic route, while midodrine mimics one component of norepinephrine's action directly at the receptor.
Option A: Option A is incorrect because it inverts the mechanisms — midodrine (not droxidopa) is the direct alpha-1 agonist, and droxidopa (not midodrine) is the precursor prodrug that generates norepinephrine.
Option B: Option B is incorrect because droxidopa is not a norepinephrine reuptake inhibitor; reuptake inhibition is the mechanism of agents such as duloxetine and tricyclic antidepressants, not droxidopa.
Option C: Option C is incorrect because droxidopa is not a mineralocorticoid and does not act through plasma volume expansion; that description correctly applies to fludrocortisone, a distinct agent used off-label for neurogenic OH.
Option E: Option E is incorrect because the two drugs do not share the same mechanism — droxidopa generates norepinephrine through enzymatic conversion while midodrine generates a direct alpha-1 agonist — and the duration-of-action distinction described is not the pharmacologically accurate differentiator.
5. Fludrocortisone is used off-label for neurogenic orthostatic hypotension in Parkinson's disease when FDA-approved agents provide insufficient blood pressure support. Which of the following correctly identifies fludrocortisone's mechanism of action and the three primary monitoring requirements that accompany its use?
A) Fludrocortisone is a glucocorticoid that reduces vascular inflammation and improves baroreceptor sensitivity; monitoring focuses on hyperglycemia, adrenal suppression, and osteoporosis with long-term use
B) Fludrocortisone is a mineralocorticoid that raises blood pressure by promoting renal sodium and water retention, thereby expanding plasma volume; patients require monitoring for supine hypertension, heart failure exacerbation, and hypokalemia
C) Fludrocortisone is a synthetic catecholamine precursor that increases norepinephrine synthesis in postganglionic sympathetic neurons; monitoring focuses on tachycardia, tremor exacerbation, and dopaminergic drug interactions
D) Fludrocortisone acts as a peripheral alpha-1 agonist with a prolonged duration of action due to its high plasma protein binding; monitoring focuses on urinary retention, digital ischemia, and reflex bradycardia from sustained vasoconstriction
E) Fludrocortisone blocks the enzyme aldosterone synthase, reducing aldosterone production and thereby lowering the sodium retention that contributes to supine hypertension in PD; monitoring focuses on hyponatremia and hyperkalemia
ANSWER: B
Rationale:
Fludrocortisone is a synthetic mineralocorticoid with potent aldosterone-like activity and minimal glucocorticoid effect at the doses used for orthostatic hypotension (0.1–0.2 mg/day). It binds to mineralocorticoid receptors in the renal collecting duct, promoting sodium reabsorption and water retention, which expands plasma volume and raises blood pressure. The three primary monitoring concerns are: supine hypertension (the same plasma volume expansion that raises standing blood pressure also raises supine blood pressure, which can reach dangerous levels); heart failure exacerbation (volume expansion can precipitate or worsen heart failure in susceptible patients); and hypokalemia (sodium reabsorption in exchange for potassium secretion depletes serum potassium, which can cause weakness, arrhythmias, and in the PD context, may worsen muscle cramps).
Option A: Option A is incorrect because fludrocortisone is a mineralocorticoid, not primarily a glucocorticoid — at the doses used for OH, glucocorticoid effects are minimal; the monitoring targets for glucocorticoid therapy (hyperglycemia, adrenal suppression, osteoporosis) are not the primary concerns at mineralocorticoid doses.
Option C: Option C is incorrect because fludrocortisone is not a catecholamine precursor and does not increase norepinephrine synthesis; this mechanism describes droxidopa, not fludrocortisone.
Option D: Option D is incorrect because fludrocortisone is not an alpha-1 agonist; urinary retention and digital ischemia are adverse effects associated with direct alpha-1 agonists such as midodrine, not with mineralocorticoids.
Option E: Option E is incorrect because fludrocortisone does not block aldosterone synthase — it mimics aldosterone by acting as a mineralocorticoid agonist; blocking aldosterone synthase would be the mechanism of an entirely different drug class used to lower blood pressure, not raise it.
6. A patient with Parkinson's disease develops nausea related to levodopa initiation. The treating team needs an antiemetic that will not worsen motor symptoms. Domperidone is selected as the preferred agent over metoclopramide. Which of the following correctly explains the pharmacological basis for domperidone's safety advantage in this context?
A) Domperidone is a dopamine D2 receptor antagonist that acts peripherally on the chemoreceptor trigger zone and gastrointestinal tract but does not cross the blood-brain barrier at standard doses, thereby providing antiemetic efficacy without central dopamine blockade that would worsen parkinsonism
B) Domperidone selectively antagonizes dopamine D3 receptors in the gastrointestinal tract while sparing D2 receptors in the basal ganglia, producing antiemetic effects without motor consequences through receptor subtype selectivity
C) Domperidone is a serotonin 5-HT3 antagonist — the same class as ondansetron — that suppresses nausea through vagal afferent blockade without any dopaminergic mechanism, making it inherently safe in Parkinson's disease
D) Domperidone crosses the blood-brain barrier but has high selectivity for D2 receptors in the area postrema rather than the striatum, producing antiemetic effects with acceptably low motor risk compared to metoclopramide
E) Domperidone is an acetylcholinesterase inhibitor that suppresses nausea by reducing the cholinergic hyperstimulation of the gut that drives levodopa-induced nausea, without affecting dopamine receptors in either the gut or the brain
ANSWER: A
Rationale:
Domperidone is a peripherally acting dopamine D2 receptor antagonist. Its key pharmacological distinction from metoclopramide is that it does not cross the blood-brain barrier at standard therapeutic doses, owing to its physicochemical properties and its status as a substrate for P-glycoprotein-mediated efflux at the blood-brain barrier. The chemoreceptor trigger zone, where domperidone exerts its primary antiemetic effect, lies outside the blood-brain barrier in the area postrema, so peripheral D2 blockade at this site is sufficient for antiemetic efficacy. Because central D2 receptors in the basal ganglia are not blocked, domperidone does not cause the motor worsening that makes metoclopramide contraindicated in PD.
Option B: Option B is incorrect because domperidone is not a selective D3 receptor antagonist — it is a D2 antagonist; its safety advantage is conferred by limited CNS penetration, not receptor subtype selectivity within the brain.
Option C: Option C is incorrect because domperidone is not a 5-HT3 antagonist; it is a dopamine D2 antagonist. Ondansetron is a 5-HT3 antagonist and is also a safe antiemetic choice in PD, but the two drugs act through entirely different receptor mechanisms.
Option D: Option D is incorrect because domperidone does not cross the blood-brain barrier at standard doses — the premise that it enters the CNS and selectively targets the area postrema over the striatum is pharmacologically inaccurate; its safety profile is based on peripheral restriction, not central selectivity.
Option E: Option E is incorrect because domperidone is not an acetylcholinesterase inhibitor and does not act through cholinergic mechanisms; acetylcholinesterase inhibition describes rivastigmine and donepezil, used for cognitive symptoms in PDD.
7. The pivotal clinical trial that supported FDA approval of pimavanserin for Parkinson's disease psychosis was the ACP-103-020 trial. Which of the following correctly summarizes the key efficacy findings of that trial?
A) The ACP-103-020 trial demonstrated a 37% reduction in motor symptoms as measured by the UPDRS Part III score compared to placebo after 12 weeks of pimavanserin 34 mg once daily, establishing that antipsychotic treatment does not necessarily worsen motor function in PD
B) The ACP-103-020 trial demonstrated that pimavanserin 34 mg once daily eliminated visual hallucinations in 72% of patients after six weeks, compared to complete elimination in 18% of placebo-treated patients, establishing it as the most effective treatment for PD psychosis across all outcome measures
C) The ACP-103-020 trial demonstrated a 37% reduction in the Scale for Assessment of Positive Symptoms adapted for PD (SAPS-PD) score compared to placebo after six weeks of treatment with pimavanserin 34 mg once daily, with no worsening of motor function
D) The ACP-103-020 trial demonstrated that pimavanserin achieved non-inferiority to low-dose clozapine on the SAPS-PD scale after 12 weeks, with a more favorable safety profile due to the absence of agranulocytosis risk
E) The ACP-103-020 trial demonstrated a statistically significant reduction in caregiver burden as its primary endpoint, with psychosis scores as a secondary endpoint; the FDA approved pimavanserin based on the caregiver burden data because SAPS-PD did not reach statistical significance in the intention-to-treat analysis
ANSWER: C
Rationale:
The ACP-103-020 trial was the pivotal phase III trial for pimavanserin in Parkinson's disease psychosis. It demonstrated a 37% reduction in the Scale for Assessment of Positive Symptoms adapted for Parkinson's disease (SAPS-PD) — a validated instrument measuring the severity of hallucinations and delusions — compared to placebo after six weeks of treatment with pimavanserin 34 mg once daily. Crucially, this antipsychotic benefit was achieved without worsening of motor function, consistent with pimavanserin's mechanism as a 5-HT2A/2C inverse agonist with no dopamine receptor binding. These results supported the FDA approval of pimavanserin as the first and only medication specifically indicated for hallucinations and delusions associated with PD psychosis.
Option A: Option A is incorrect because the ACP-103-020 trial measured psychotic symptoms — not motor symptoms — as its primary endpoint using the SAPS-PD scale, not the UPDRS Part III motor scale; and the trial duration was six weeks, not 12.
Option B: Option B is incorrect because the trial result was a 37% relative reduction in SAPS-PD score, not an absolute elimination rate in 72% of patients; the description of "complete elimination" rates does not reflect the actual trial methodology or results.
Option D: Option D is incorrect because the ACP-103-020 trial was a placebo-controlled trial, not a head-to-head comparison against clozapine; pimavanserin has not been compared to clozapine in a non-inferiority trial.
Option E: Option E is incorrect because caregiver burden was not the primary endpoint of the ACP-103-020 trial; the SAPS-PD was the primary efficacy endpoint, and the trial did achieve statistical significance on this measure, which formed the basis of the FDA approval.
8. A patient with Parkinson's disease on rasagiline develops depression and the treating clinician considers adding an SSRI. Concern is raised about the combination of an MAO-B inhibitor with a serotonergic antidepressant. Which of the following most accurately characterizes the risk of this combination and the correct clinical approach?
A) The combination of any MAO-B inhibitor with any SSRI is absolutely contraindicated and carries the same risk of fatal serotonin syndrome as combining a non-selective MAOI with an SSRI; the SSRI must be stopped and a two-week washout observed before any MAO-B inhibitor can be initiated
B) MAO-B inhibitors such as rasagiline and selegiline have no serotonergic activity whatsoever at any dose, making co-administration with SSRIs or SNRIs completely safe; the interaction warning in prescribing information is a class label applied without pharmacological basis
C) The risk of serotonin syndrome with the MAO-B inhibitor and SSRI combination is specific to selegiline but not rasagiline, because selegiline is metabolized to amphetamine derivatives that independently increase synaptic serotonin; rasagiline can be freely combined with any SSRI
D) The combination is safe provided the SSRI dose does not exceed 50% of the standard therapeutic dose; above this threshold, the serotonergic load exceeds the capacity of MAO-B to metabolize excess serotonin and syndrome risk increases exponentially
E) While selective MAO-B inhibitors carry substantially lower serotonin syndrome risk than non-selective MAOIs when combined with SSRIs or SNRIs, the combination still warrants clinical monitoring; the risk is reduced but not zero, and individual variability exists
ANSWER: E
Rationale:
Selective MAO-B inhibitors at standard therapeutic doses act predominantly on MAO-B, which metabolizes dopamine, rather than on MAO-A, the isoform chiefly responsible for metabolizing serotonin. This is the basis for the substantially lower serotonin syndrome risk compared to non-selective monoamine oxidase inhibitors (MAOIs), where co-administration with any serotonergic agent carries a high risk of potentially fatal serotonin syndrome. The published clinical experience with MAO-B inhibitor plus SSRI/SNRI combinations in Parkinson's disease is reassuring: across multiple cohort and survey studies the combination is generally well tolerated and serotonin syndrome is rare, with reported cases typically mild and resolving on discontinuation or dose reduction. The risk is nonetheless not zero, and the mechanism underlying the rare events is not firmly established. Accordingly, the combination is widely used but warrants sensible precautions — keeping the MAO-B inhibitor at its recommended dose, keeping the SSRI or SNRI at the lower end of its therapeutic range, and monitoring for early signs of serotonin syndrome (tremor, diaphoresis, agitation, clonus, hyperthermia). Paroxetine in particular is identified in prescribing information as contraindicated with MAO-B inhibitors and should be avoided.
Option A: Option A is incorrect because equating the risk of selective MAO-B inhibitors with non-selective MAOIs overstates the danger and would deprive PD patients with depression of an important and widely used treatment combination; the risk profile is substantially different between the two inhibitor classes.
Option B: Option B is incorrect because it overstates the safety in absolute terms: although the combination is generally well tolerated and serotonin syndrome is rare, the risk is not zero, and rare cases are documented in the literature. The claim that MAO-B inhibitors have “no serotonergic activity whatsoever” and that the labeling caution has “no pharmacological basis” is too strong — the interaction caution reflects genuine, if uncommon, clinical risk, and the appropriate posture is sensible precaution (recommended dosing, lower-range SSRI dose, monitoring), not dismissal of the interaction.
Option C: Option C is incorrect because of its absolute framing — the claim that rasagiline “can be freely combined with any SSRI” is unsafe. While rasagiline does have somewhat greater MAO-B specificity than selegiline and the available data suggest it is at least as well tolerated (the largest cohort found no serotonin syndrome cases with rasagiline plus an SSRI), this is a difference of degree, not a license for unrestricted combination; prescribing information for both agents includes an interaction caution, and monitoring with sensible dosing remains appropriate for either drug.
Option D: Option D is incorrect because there is no validated dose-threshold rule for SSRI use with MAO-B inhibitors; the 50% dose ceiling described is not a recognized clinical standard and implies a false precision about the risk relationship.
9. Botulinum toxin injection is used for sialorrhea management in advanced Parkinson's disease. Which of the following correctly describes the mechanism, target glands, duration of effect, and the specific clinical circumstance in which botulinum toxin is particularly preferred over oral pharmacological options?
A) Botulinum toxin is injected into the sublingual and minor salivary glands, where it irreversibly destroys the acinar cells responsible for saliva production; it is preferred in patients with swallowing dysfunction because it eliminates rather than merely reduces salivary output
B) Botulinum toxin is injected into the parotid and submandibular glands, where it blocks acetylcholine release at parasympathetic nerve terminals to reduce salivary secretion; effect lasts three to six months, and it is particularly preferred in patients with cognitive impairment where oral anticholinergic agents carry unacceptable cognitive risk
C) Botulinum toxin is injected into the parotid glands only, where it blocks muscarinic M3 receptors directly on acinar cell membranes; duration of effect is 12 to 18 months because receptor blockade persists until new receptor protein is synthesized
D) Botulinum toxin for sialorrhea is administered as a weekly sublingual tablet that is absorbed through the oral mucosa into the local salivary gland vasculature; it is preferred in outpatient settings because it avoids the procedural complexity and cost of injection
E) Botulinum toxin is injected intramuscularly into the masseter and pterygoid muscles to reduce chewing-induced salivary stimulation; it is preferred in patients with severe trismus because it simultaneously treats trismus and reduces mechanical salivary drive
ANSWER: B
Rationale:
Botulinum toxin type A or B is injected directly into the parotid glands and submandibular glands — the major salivary glands responsible for the majority of saliva production. It acts by blocking the calcium-dependent release of acetylcholine from parasympathetic nerve terminals supplying the glandular acini, thereby reducing cholinergically driven salivary secretion. The clinical effect typically lasts three to six months, after which reinjection is required as new nerve terminal proteins are synthesized and acetylcholine release is restored. Botulinum toxin injection is particularly valuable in patients with cognitive impairment, in whom oral anticholinergic agents — including glycopyrrolate — carry meaningful cognitive risk even at peripherally restricted doses, and in whom the systemic adverse effect burden of oral agents is undesirable.
Option A: Option A is incorrect because botulinum toxin does not destroy acinar cells — it produces a reversible functional block of neurotransmitter release from nerve terminals; the glandular tissue itself is preserved, and the effect reverses as new presynaptic proteins are synthesized.
Option C: Option C is incorrect on two counts: botulinum toxin targets both parotid and submandibular glands, not the parotid alone; and it acts at presynaptic nerve terminals to block acetylcholine release, not directly at muscarinic receptors on acinar cells — receptor blockade is the mechanism of anticholinergic drugs, not botulinum toxin.
Option D: Option D is incorrect because botulinum toxin for sialorrhea is administered by glandular injection, not as a sublingual tablet; no sublingual tablet formulation of botulinum toxin for this indication exists.
Option E: Option E is incorrect because the target for sialorrhea treatment is the salivary glands themselves, not the muscles of mastication; masseter and pterygoid injections address bruxism or jaw dystonia, not salivary secretion.
10. REM sleep behavior disorder (RBD) is increasingly recognized as more than a complication of established Parkinson's disease. Which of the following correctly describes its relationship to the synucleinopathy disease process and the clinical implication of this relationship?
A) RBD develops exclusively in patients who already have established motor Parkinson's disease for at least five years; its presence in a patient without motor symptoms should prompt evaluation for a non-synucleinopathy cause such as brainstem structural lesion or medication effect
B) RBD is a highly sensitive but non-specific marker of synucleinopathy — it occurs in approximately 80% of all patients with any neurodegenerative disease, including Alzheimer's disease and frontotemporal dementia, and therefore has limited diagnostic utility for distinguishing PD from other dementias
C) RBD in PD is caused exclusively by the dopaminergic depletion that drives motor symptoms; successful treatment of motor fluctuations with levodopa optimization reliably resolves RBD because the same dopaminergic pathways control both motor function and REM atonia
D) RBD often precedes the motor symptoms of Parkinson's disease by a decade or more and carries high specificity for subsequent Lewy body disease, making it a recognized prodromal feature of synucleinopathies with implications for early disease identification and neuroprotection research
E) RBD is a late-stage complication that develops only after the onset of Parkinson's disease dementia, reflecting the spread of Lewy body pathology from subcortical to cortical regions in Braak stages 5 and 6
ANSWER: D
Rationale:
REM sleep behavior disorder has been established as a prodromal feature of synucleinopathies — the group of neurodegenerative diseases characterized by alpha-synuclein aggregation, which includes Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Longitudinal studies have demonstrated that idiopathic RBD (RBD without an identified cause) precedes the clinical motor or cognitive onset of a synucleinopathy by a decade or more in the majority of affected individuals, with conversion rates approaching 80–90% over 10–15 years of follow-up. The high specificity of RBD for synucleinopathy — as distinct from Alzheimer's disease or other non-synucleinopathy dementias — gives it diagnostic significance in prodromal disease identification. This relationship has positioned idiopathic RBD as a key entry criterion for neuroprotection trials aimed at intervening before overt neurodegeneration causes irreversible disability.
Option A: Option A is incorrect because RBD frequently precedes motor PD by years or decades; its occurrence in a patient without established motor PD is not an indication to search for alternative causes — it is a recognized prodromal state.
Option B: Option B is incorrect because RBD is relatively specific for synucleinopathies rather than broadly occurring across all neurodegenerative diseases; it is not a feature of Alzheimer's disease with the same frequency or specificity.
Option C: Option C is incorrect because RBD is not caused by dopaminergic depletion in the nigrostriatal pathway; it arises from degeneration of brainstem structures controlling REM atonia — particularly the sublaterodorsal nucleus and related circuits — and does not reliably respond to levodopa optimization.
Option E: Option E is incorrect because RBD frequently appears in the prodromal phase of PD, well before dementia develops; restricting its occurrence to Braak stages 5 and 6 is inconsistent with the established evidence that RBD can precede all other PD symptoms by many years.
11. A patient with Parkinson's disease has been taking low-dose pramipexole for restless legs syndrome for 18 months. She reports that her symptoms, which were initially well-controlled, have become worse despite dose increases — they now begin in the afternoon rather than the evening, affect her arms as well as her legs, and are more intense than before she started treatment. Which of the following correctly identifies this phenomenon and distinguishes it from the other explanations that must be excluded?
A) This is augmentation — a recognized complication of dopamine agonist therapy for RLS characterized by paradoxical worsening of symptoms with prolonged use, including earlier symptom onset, spread to previously unaffected body parts, and greater intensity; it is distinct from disease progression (which would not be causally linked to dose escalation) and from tolerance (which is loss of efficacy at a stable dose without the characteristic spread and temporal shift)
B) This is rebound — a pharmacokinetic phenomenon in which RLS symptoms emerge with greater intensity during the period of lowest plasma drug concentration (typically early morning), reflecting the predictable off-period effect of a short-acting dopamine agonist; the correct intervention is switching to a longer-acting formulation
C) This is tolerance — a pharmacodynamic phenomenon in which dopamine D3 receptors in the spinal cord are downregulated in response to chronic agonist exposure, requiring progressively higher doses to achieve the same receptor occupancy; gabapentin enacarbil is preferred because it acts through a receptor system not subject to downregulation
D) This is dopamine dysregulation syndrome — a compulsive pattern of dopaminergic medication use driven by mesolimbic reward pathway sensitization; the characteristic feature is that patients feel compelled to take more medication than clinically necessary, and symptom reports are disproportionate to objective disease severity
E) This is disease progression of the underlying RLS, which is an independent neurodegenerative condition that worsens regardless of pharmacological management; dose escalation is the appropriate response and should be continued until symptom control is restored or adverse effects intervene
ANSWER: A
Rationale:
Augmentation is the most clinically important long-term complication of dopamine agonist therapy for restless legs syndrome and is defined by a specific triad that differentiates it from other explanations: earlier daily onset of symptoms (shifting from evening to afternoon or even daytime), spread to body parts previously unaffected (from legs to arms), and increased symptom intensity — all occurring in the context of dose escalation that fails to provide lasting relief and may paradoxically worsen the syndrome. The key distinction from tolerance is that tolerance is loss of efficacy at a stable dose without the temporal shift and anatomical spread that characterize augmentation; augmentation involves a qualitative worsening of the syndrome's features, not merely a reduction in drug effect. Disease progression, by contrast, would not be causally accelerated by the dopamine agonist treatment itself. When augmentation is identified, the correct management involves transitioning away from the dopamine agonist toward an alpha-2-delta calcium channel ligand (gabapentin enacarbil or pregabalin), which do not cause augmentation.
Option B: Option B is incorrect because rebound refers to a transient waking in the early morning hours at the nadir of drug effect — it is a pharmacokinetic phenomenon and does not explain the daytime onset, spread to the arms, and overall worsening trajectory described; rebound is also reversible with formulation adjustment alone.
Option C: Option C is incorrect because while D3 receptor downregulation is a plausible mechanistic contributor, the clinical phenomenon described is augmentation, not tolerance in the narrow pharmacodynamic sense; tolerance does not produce the characteristic earlier-onset, spreading pattern.
Option D: Option D is incorrect because dopamine dysregulation syndrome is characterized by compulsive reward-driven medication-seeking behavior, not by the specific spatiotemporal worsening pattern of RLS that defines augmentation.
Option E: Option E is incorrect because RLS is not a progressive neurodegenerative condition in the same sense as PD, and the pattern described — worsening causally linked to dose escalation over an 18-month treatment course — is the clinical signature of augmentation, not independent disease progression.
12. Modafinil is used for excessive daytime sleepiness in Parkinson's disease. Its mechanism of action is frequently contrasted with that of classical stimulants such as amphetamine. Which of the following most accurately describes modafinil's wake-promoting mechanism and how it differs from amphetamine?
A) Modafinil selectively blocks adenosine A2A receptors in the basal ganglia and wake-promoting nuclei, reducing the adenosinergic sleep drive that accumulates during wakefulness; this mechanism is shared with caffeine but produces longer-lasting wakefulness due to higher receptor affinity
B) Modafinil is a dopamine reuptake inhibitor with a binding profile identical to cocaine at the dopamine transporter, but its slower onset and lower peak dopamine concentrations produce wakefulness without the reinforcing subjective effects that characterize cocaine and amphetamine
C) Modafinil directly activates hypocretin/orexin neurons in the lateral hypothalamus by acting as an orexin receptor agonist, replacing the orexin signaling lost through neurodegeneration in PD; this makes it mechanistically superior to amphetamine, which bypasses orexin circuits entirely
D) Modafinil blocks norepinephrine reuptake at locus coeruleus terminals projecting to the cortex, increasing noradrenergic arousal tone; this is identical to the mechanism of atomoxetine, and both drugs are equally effective for excessive daytime sleepiness in PD
E) Modafinil promotes wakefulness through mechanisms involving modulation of hypothalamic orexin circuits, histaminergic pathways, and reduced GABA release in arousal-relevant regions, without causing the dopamine flood-release that characterizes amphetamine; its precise molecular target remains incompletely characterized
ANSWER: E
Rationale:
Modafinil's wake-promoting mechanism is not fully characterized at the molecular level, which distinguishes it from classical stimulants with well-defined primary mechanisms. Current evidence implicates modulation of hypothalamic hypocretin/orexin circuits (which regulate arousal and wakefulness), histaminergic pathways projecting from the tuberomammillary nucleus, and reduced GABA release in wake-promoting brain regions. This combination of mechanisms promotes wakefulness without the massive catecholamine flood-release — particularly dopamine — that characterizes amphetamine and methamphetamine. Amphetamine causes non-vesicular dopamine release from nerve terminals through reversal of the dopamine transporter, producing rapid, high-amplitude dopamine surges that drive the reinforcing and cardiovascular effects associated with that class. Modafinil does have some interaction with the dopamine transporter, but this does not produce the same magnitude of dopamine release. The result is effective wake promotion with a substantially lower abuse potential and cardiovascular risk profile compared to amphetamine.
Option A: Option A is incorrect because adenosine A2A receptor blockade is the mechanism of caffeine and certain experimental compounds, not modafinil; while adenosine and orexin systems interact in sleep-wake regulation, adenosine receptor blockade is not the established mechanism of modafinil.
Option B: Option B is incorrect because while modafinil does have some interaction with the dopamine transporter, characterizing it as a dopamine reuptake inhibitor with a binding profile "identical to cocaine" overstates the pharmacological similarity and misrepresents modafinil's mechanism, which is broader and less defined than cocaine's primary dopamine transporter blockade.
Option C: Option C is incorrect because modafinil is not an orexin receptor agonist — it interacts with orexin circuits indirectly rather than acting as a direct receptor agonist; no approved orexin receptor agonist exists for clinical use for this indication.
Option D: Option D is incorrect because while modafinil may have noradrenergic effects, characterizing it as a norepinephrine reuptake inhibitor "identical to atomoxetine" is pharmacologically inaccurate; atomoxetine is a selective norepinephrine reuptake inhibitor not approved or established as equivalent to modafinil for EDS in PD.
13. A clinical pharmacologist is comparing midodrine and droxidopa for a patient with Parkinson's disease and neurogenic orthostatic hypotension. Both are FDA-approved for this indication. Which of the following most precisely and correctly contrasts the two agents across mechanism, prodrug status, and active pharmacological species?
A) Both midodrine and droxidopa are direct-acting peripheral vasoconstrictors that require no metabolic conversion; midodrine acts on alpha-1 receptors and droxidopa acts on alpha-2 receptors, producing vasoconstriction through distinct receptor subtypes on arteriolar smooth muscle
B) Midodrine is an active drug that directly stimulates peripheral alpha-1 receptors without requiring metabolic conversion, while droxidopa is a prodrug converted to desglymidodrine — a direct alpha-1 agonist — by plasma esterases; both ultimately produce vasoconstriction through the same receptor subtype
C) Both midodrine and droxidopa are prodrugs, but through different conversion pathways: midodrine is converted to desglymidodrine (a direct alpha-1 agonist) by plasma esterases, while droxidopa is converted to norepinephrine by aromatic L-amino acid decarboxylase; the two drugs therefore raise blood pressure through different pharmacological mechanisms
D) Droxidopa is the preferred first-line agent over midodrine because it restores the physiological neurotransmitter norepinephrine, which activates alpha-1, alpha-2, and beta-1 receptors simultaneously, producing a broader hemodynamic response than midodrine's selective alpha-1 agonism; FDA labeling reflects this superiority
E) Midodrine is a prodrug converted to desglymidodrine by aromatic L-amino acid decarboxylase, while droxidopa is a prodrug converted to norepinephrine by plasma cholinesterases; the difference in converting enzymes explains why droxidopa has a faster onset of action than midodrine
ANSWER: C
Rationale:
Both midodrine and droxidopa are prodrugs, but they are converted to pharmacologically active species by different enzymes and produce blood pressure elevation through distinct mechanisms. Midodrine is a prodrug that is converted to desglymidodrine by plasma esterases; desglymidodrine is a direct, selective peripheral alpha-1 adrenergic agonist that causes arteriolar and venous constriction, increasing both vascular resistance and venous return. Droxidopa is a synthetic amino acid prodrug that is converted to norepinephrine by aromatic L-amino acid decarboxylase (AADC) — the same enzyme that converts levodopa to dopamine. The resulting norepinephrine acts on alpha-1, alpha-2, and beta-1 adrenergic receptors, raising blood pressure through both vasoconstriction and increased cardiac output. The two agents are therefore pharmacologically distinct despite sharing the same indication.
Option A: Option A is incorrect because both drugs are prodrugs requiring metabolic conversion, not direct-acting agents; and droxidopa does not act on alpha-2 receptors selectively — it generates norepinephrine, which has broad adrenergic activity.
Option B: Option B is incorrect because it inverts the prodrug relationship — midodrine (not droxidopa) is converted to desglymidodrine; droxidopa is converted to norepinephrine, not desglymidodrine.
Option D: Option D is incorrect because FDA labeling does not establish droxidopa as superior to midodrine; both carry the same indication for neurogenic orthostatic hypotension, and selection between them is based on individual patient factors, not a hierarchy of efficacy established by regulatory labeling.
Option E: Option E is incorrect because it assigns the wrong converting enzyme to each drug — midodrine is converted by plasma esterases, not AADC; and droxidopa is converted by AADC, not plasma cholinesterases; inverting these enzymes reverses the actual pharmacology of both agents.
14. A 69-year-old man with Parkinson's disease reports a painful, sustained involuntary inversion and plantar flexion of his right foot that occurs every morning before his first levodopa dose and resolves within 30 minutes of taking it. The treating neurologist identifies this as off-period foot dystonia — a form of dopaminergically responsive pain — and considers both pharmacological and procedural interventions. Which of the following correctly identifies the two most appropriate targeted treatments for this specific presentation?
A) Oral baclofen and diazepam are the two treatments of choice for off-period dystonic pain because they act on GABA-B and GABA-A receptors respectively in spinal interneuron circuits, directly suppressing the dystonic motor program independent of dopaminergic state
B) Optimizing the levodopa regimen to reduce the duration and frequency of off periods (for example by adding a COMT inhibitor or a bedtime controlled-release dose) and botulinum toxin injection into the affected foot and calf muscles are the two most directly targeted treatments for off-period dystonic pain
C) Oral pregabalin and duloxetine are the appropriate pharmacological combination because off-period dystonic pain has a neuropathic component driven by sensitization of spinal dorsal horn neurons during repeated off periods, and dual mechanism analgesia achieves superior pain control to either agent alone
D) Transcutaneous electrical nerve stimulation and physiotherapy are the evidence-based first-line treatments for off-period dystonic pain; pharmacological interventions are reserved for refractory cases because they add to an already complex medication burden
E) Deep brain stimulation of the subthalamic nucleus is the only reliably effective treatment for off-period dystonic pain because pharmacological management of off periods does not adequately suppress the abnormal pallidal output driving the dystonic posture
ANSWER: B
Rationale:
Off-period foot dystonia is a form of pain that is directly driven by sub-therapeutic levodopa concentrations causing abnormal dystonic muscle contraction during the off state. Because it is dopaminergically responsive — it resolves when levodopa levels rise — the primary pharmacological intervention is optimization of the levodopa regimen to shorten or eliminate the off period. This can be achieved by adding a COMT inhibitor (entacapone or opicapone) to extend levodopa's duration of action, by administering a controlled-release carbidopa/levodopa formulation at bedtime to maintain coverage through the early morning, or by adjusting dosing intervals. For the specific muscle groups responsible for the dystonic posture — typically the tibialis posterior, gastrocnemius, and foot intrinsic muscles — botulinum toxin injection directly reduces the abnormal muscle contraction, providing targeted relief that is particularly useful when levodopa optimization alone does not fully control the dystonia or when levodopa dose increases are limited by other adverse effects.
Option A: Option A is incorrect because while baclofen and benzodiazepines can reduce dystonic muscle activity through GABAergic mechanisms, they are not the primary targeted treatments for off-period dystonic pain in PD — they do not address the dopaminergic mechanism driving the off-period state and carry sedation and fall risk.
Option C: Option C is incorrect because off-period dystonic pain is a dopaminergically responsive motor phenomenon, not primarily a neuropathic pain syndrome; pregabalin and duloxetine may have a role in PD pain of neuropathic subtype but are not the targeted treatment for dopaminergically responsive off-period dystonia.
Option D: Option D is incorrect because physiotherapy and TENS do not address the pharmacological mechanism driving off-period dystonia; while rehabilitation has a role in PD management, characterizing these as evidence-based first-line treatments over dopaminergic optimization and botulinum toxin for this specific indication misrepresents the evidence hierarchy.
Option E: Option E is incorrect because while deep brain stimulation is highly effective for motor fluctuations including painful off-period dystonia in appropriately selected patients, it is a surgical intervention reserved for patients who have not responded to optimized medical management — it is not the only reliably effective treatment, and pharmacological optimization remains the appropriate first step.
15. Constipation affects up to 80% of patients with Parkinson's disease, reflecting both intrinsic enteric nervous system Lewy body pathology and the constipating effects of dopaminergic medications. First-line management includes macrogol (polyethylene glycol) laxatives, increased dietary fiber, and adequate hydration. For refractory constipation that does not respond to these measures, a pharmacological agent acting through a distinct mechanism is available. Which of the following correctly identifies this agent and its mechanism?
A) Lubiprostone, a chloride channel activator that increases intestinal fluid secretion by opening ClC-2 chloride channels in intestinal epithelial cells, is the standard second-line agent for constipation in PD and has specific FDA approval for opioid-induced constipation in PD patients on opioid analgesics
B) Naloxegol, a peripherally acting mu-opioid receptor antagonist, is the appropriate second-line agent for all PD-related constipation because the primary mechanism of constipation in PD is opioid-mediated — enteric opioid peptides are upregulated as a consequence of dopaminergic denervation of the enteric nervous system
C) Lactulose, an osmotic laxative that works through the same mechanism as macrogol but with a longer duration of action, is the preferred second-line agent because its bacterial fermentation in the colon produces short-chain fatty acids that additionally stimulate enteric nervous system neurons
D) Prucalopride, a selective high-affinity serotonin 5-HT4 receptor agonist, is an option for refractory constipation in PD; it acts by stimulating 5-HT4 receptors on enteric neurons and smooth muscle to accelerate colonic transit, through a mechanism entirely distinct from the osmotic action of macrogol
E) Metoclopramide is the appropriate prokinetic agent for refractory constipation in PD because it accelerates gastric emptying and colonic transit through combined D2 blockade and 5-HT4 agonism, and its central D2 effects are negligible at the low doses required for constipation treatment
ANSWER: D
Rationale:
Prucalopride is a selective, high-affinity serotonin 5-HT4 receptor agonist that promotes colonic transit by stimulating 5-HT4 receptors on intrinsic enteric neurons and smooth muscle cells within the colon. Activation of 5-HT4 receptors in the enteric nervous system enhances the release of acetylcholine from myenteric plexus neurons, increasing peristaltic activity and accelerating colonic transit. This mechanism is entirely distinct from the osmotic mechanism of macrogol (polyethylene glycol), which retains water in the colonic lumen by osmotic pressure. Prucalopride has high selectivity for 5-HT4 receptors over other serotonin receptor subtypes and cardiac ion channels, which gives it a favorable safety profile compared to earlier prokinetics in this class.
Option A: Option A is incorrect because lubiprostone, while a valid treatment for chronic idiopathic constipation, is not specifically approved for PD-related constipation and is not the standard second-line agent for this population; furthermore, it activates ClC-2 chloride channels, not 5-HT4 receptors.
Option B: Option B is incorrect because naloxegol is specifically indicated for opioid-induced constipation, not for the enteric nervous system Lewy body pathology that drives constipation in PD; opioid receptor upregulation secondary to dopaminergic denervation is not the established primary mechanism of constipation in PD.
Option C: Option C is incorrect because lactulose is not the preferred second-line agent for refractory constipation in PD — it produces significant bloating and flatulence from bacterial fermentation and is not more effective than macrogol for PD constipation; it does not act through a meaningfully distinct mechanism from macrogol in clinical practice.
Option E: Option E is incorrect and represents a dangerous error: metoclopramide is contraindicated in Parkinson's disease because its central D2 receptor blockade causes severe motor worsening regardless of dose; characterizing its central D2 effects as "negligible at low doses" is pharmacologically inaccurate and clinically hazardous.
16. Quetiapine is sometimes used at low doses (12.5–50 mg) in patients with Parkinson's disease for psychosis or insomnia. Which of the following most accurately characterizes quetiapine's position relative to other antipsychotic agents used in PD, specifically regarding motor risk and efficacy evidence?
A) Quetiapine carries less motor risk than risperidone in Parkinson's disease due to lower D2 receptor occupancy at low doses, but carries more motor risk than pimavanserin or low-dose clozapine; its efficacy for Parkinson's disease psychosis is supported by limited clinical data, and it lacks a formal PDP indication
B) Quetiapine is equivalent to pimavanserin in motor safety because both agents have zero D2 receptor binding affinity at all clinically used doses; quetiapine is preferred over pimavanserin in practice because it additionally treats insomnia and depression, providing multi-symptom benefit
C) Quetiapine carries the same degree of motor risk as haloperidol in Parkinson's disease because both agents block D2 receptors; the difference is that quetiapine's shorter half-life allows motor worsening to resolve more quickly after discontinuation, making it the safer choice among D2-blocking agents in PD
D) Quetiapine is the first-line pharmacological treatment for Parkinson's disease psychosis according to all major movement disorder society guidelines because it has the most extensive randomized controlled trial evidence among antipsychotics used in this population, with four pivotal trials demonstrating superiority over placebo
E) Quetiapine has a black-box warning specific to its use in Parkinson's disease — separate from the class warning shared by all antipsychotics — because clinical trials demonstrated an approximately fourfold increase in mortality in PD patients compared to placebo, a risk not observed with pimavanserin in the same population
ANSWER: A
Rationale:
Quetiapine occupies a nuanced position in the pharmacological management of Parkinson's disease psychosis. At low doses, its D2 receptor occupancy is lower than that of risperidone and most first-generation antipsychotics, giving it a more favorable motor risk profile than these agents; however, it is not free of D2 blockade and carries more motor risk than pimavanserin (which has no D2 binding) and low-dose clozapine (which has very low D2 occupancy at PDP doses). Clinically, quetiapine is used in practice for both psychosis and insomnia in PD, but its efficacy for PD psychosis specifically is supported by limited and inconsistent controlled trial evidence — randomized trials have not consistently demonstrated superiority over placebo for hallucinations and delusions in PD — and it lacks a formal FDA indication for PDP. Its use persists largely because of clinical familiarity and its sedating properties.
Option B: Option B is incorrect because quetiapine is not equivalent to pimavanserin in motor safety — quetiapine does have D2 receptor binding activity at clinical doses, unlike pimavanserin, which has no dopamine receptor affinity; equating their motor safety profiles is pharmacologically inaccurate.
Option C: Option C is incorrect because quetiapine does not carry the same degree of motor risk as haloperidol — haloperidol is a high-potency D2 blocker that causes severe parkinsonism and is contraindicated in PD; quetiapine's D2 occupancy at PDP doses is substantially lower.
Option D: Option D is incorrect because quetiapine is not recommended as first-line treatment for PDP by major movement disorder societies, and its controlled trial evidence base for PDP is limited and inconsistent rather than robust across four pivotal trials; pimavanserin holds the FDA approval for this indication.
Option E: Option E is incorrect because quetiapine does not carry a PD-specific black-box warning separate from the class warning; the mortality warning that applies to quetiapine in elderly patients with dementia-related psychosis is the same class-wide warning that applies to all atypical antipsychotics, including pimavanserin.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.